Analysts Set AxoGen, Inc. (NASDAQ:AXGN) Target Price at $13.80

Shares of AxoGen, Inc. (NASDAQ:AXGN) have received an average rating of “Buy” from the five research firms that are covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have covered the stock in the last year is $13.80.

Several brokerages recently commented on AXGN. JMP Securities upped their price target on shares of AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a research report on Friday, August 9th. Canaccord Genuity Group restated a “buy” rating and set a $15.00 price target on shares of AxoGen in a research note on Thursday, June 20th. StockNews.com upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Friday, August 9th. Finally, Raymond James assumed coverage on shares of AxoGen in a research note on Monday, July 1st. They issued an “outperform” rating and a $13.00 target price on the stock.

Hedge Funds Weigh In On AxoGen

Hedge funds and other institutional investors have recently made changes to their positions in the business. Koss Olinger Consulting LLC bought a new position in shares of AxoGen during the 2nd quarter worth about $75,000. Lazard Asset Management LLC lifted its holdings in AxoGen by 30.1% during the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after purchasing an additional 2,671 shares during the last quarter. Acadian Asset Management LLC bought a new position in AxoGen during the 2nd quarter valued at about $125,000. BNP Paribas Financial Markets lifted its holdings in AxoGen by 8.6% during the 1st quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock valued at $168,000 after purchasing an additional 1,651 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in AxoGen by 8.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,650 shares of the medical equipment provider’s stock valued at $240,000 after purchasing an additional 2,204 shares during the last quarter. 80.29% of the stock is owned by institutional investors.

AxoGen Trading Up 1.5 %

AxoGen stock opened at $13.25 on Tuesday. The firm has a 50 day simple moving average of $9.99 and a 200-day simple moving average of $8.37. The company has a debt-to-equity ratio of 0.70, a current ratio of 3.51 and a quick ratio of 2.32. The stock has a market capitalization of $579.09 million, a PE ratio of -26.50 and a beta of 1.11. AxoGen has a 12-month low of $3.45 and a 12-month high of $13.33.

AxoGen (NASDAQ:AXGN) last issued its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $47.91 million during the quarter, compared to analysts’ expectations of $43.27 million. AxoGen had a negative net margin of 9.53% and a negative return on equity of 17.30%. As a group, equities research analysts expect that AxoGen will post -0.33 EPS for the current fiscal year.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.